Leading Firms Reshaping the Future of US pneumococcal vaccine market
The U.S. pneumococcal vaccine market is experiencing significant momentum, driven by the increasing incidence of pneumococcal disease, strong government-led immunization initiatives, and rising awareness about preventive healthcare across age groups. With both conjugate vaccines and polysaccharide vaccines playing key roles in national public health strategies, the market continues to evolve in response to emerging variants and population-specific needs.
Global US Pneumococcal Vaccine Market size and share is currently valued at USD 5,239.27 million in 2024 and is anticipated to generate an estimated revenue of USD 6,511.79 million by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 2.3% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
Market Overview
Pneumococcal vaccines are essential tools in the fight against Streptococcus pneumoniae, the bacterium responsible for a wide range of infections, including pneumonia, meningitis, and bloodstream infections. These vaccines are particularly important for high-risk groups such as infants, elderly individuals, and immunocompromised patients.
In the U.S., the market is primarily categorized into two types:
Pneumococcal Conjugate Vaccines (PCVs) – such as Prevnar 13 and Prevnar 20, designed to protect against multiple serotypes using a conjugation process for improved immune response.
Pneumococcal Polysaccharide Vaccines (PPSVs) – such as Pneumovax 23, recommended for adults and those with chronic conditions.
The widespread adoption of the conjugate vaccine in pediatric and adult immunization schedules has notably reduced the burden of pneumococcal disease in the U.S., but gaps in coverage and rising antibiotic resistance continue to push demand for broader-spectrum, next-generation vaccines.
Key growth drivers include:
Rising prevalence of pneumococcal infections among aging populations
Expansion of vaccine immunization mandates by the CDC and ACIP
Technological advancements in conjugate vaccine formulations
Increase in public-private partnerships and federal funding
Growing emphasis on adult vaccination beyond traditional pediatric populations
Key Companies
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi
- GlaxoSmithKline plc
- CSL Behring
- Serum Institute
- Astellas Pharma US, Inc.
- Johnson & Johnson
- Novavax, Inc.
- Vaxcyte, Inc.
Market Segmentation
The U.S. pneumococcal vaccine market is segmented by vaccine type, age group, distribution channel, and end user.
By Vaccine Type:
Pneumococcal Conjugate Vaccine (PCV)
Pneumococcal Polysaccharide Vaccine (PPSV)
Among these, PCVs dominate the market, driven by their inclusion in routine infant immunization and increasing approval for adult use. Prevnar 20, a 20-valent conjugate vaccine, is the latest innovation expanding coverage against additional serotypes.
By Age Group:
Pediatric (0–17 years)
Adult (18–64 years)
Geriatric (65+ years)
While the pediatric segment continues to account for a significant share due to mandatory vaccination programs, the geriatric segment is witnessing the fastest growth. This is attributed to higher susceptibility to pneumonia and other secondary infections among older adults.
By Distribution Channel:
Hospitals & Clinics
Pharmacies
Public Health Agencies
Private Practitioners
Pharmacies are emerging as an important access point for vaccinations, especially among adults. The availability of walk-in services at retail pharmacies such as CVS and Walgreens is boosting uptake among working populations.
By End User:
Government & Public Institutions
Private Sector
Academic & Research Institutions
The public sector remains the largest end user due to large-scale government-funded immunization initiatives, particularly the Vaccines for Children (VFC) program and Medicare coverage for adult vaccines.
Regional Analysis
While the market study focuses on the United States as a whole, regional trends within the U.S. highlight notable differences in vaccine access, coverage, and awareness.
Northeast:
The Northeast region, including states like New York, Massachusetts, and Pennsylvania, has high immunization coverage due to strong public health infrastructure and dense urban populations. Government campaigns and proactive pediatric care models contribute to increased PCV uptake.
Midwest:
The Midwest shows steady growth, with increased partnerships between healthcare providers and community organizations to improve access in rural and suburban regions. States like Ohio and Illinois have launched targeted adult vaccination drives to reduce hospitalizations related to pneumococcal pneumonia.
South:
The Southern U.S. has traditionally lagged in adult immunization rates but is witnessing significant improvement due to rising awareness and targeted outreach efforts. Public-private collaboration in states like Texas and Florida is fueling market expansion.
West:
The Western region, including California and Washington, leads in vaccine innovation and clinical trials. High urban density, progressive healthcare policies, and investment in digital health solutions have enabled efficient vaccine rollouts, particularly among seniors and at-risk populations.
Explore More:
https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market
Future Outlook
The future of the U.S. pneumococcal vaccine market will be shaped by:
Expanding adult immunization policies and coverage under Medicare Part D and ACA regulations
Development of higher-valency conjugate vaccines to address unmet needs in protection
Integration of pneumococcal vaccines into combination platforms for pediatric use
Advancements in vaccine delivery systems, including microneedles and intranasal options
Digital tracking systems and AI-enabled vaccine forecasting to enhance coverage and supply chain efficiency
With aging demographics, evolving strains of pneumococcal disease, and renewed federal focus on preventive healthcare, the U.S. market is poised for steady and sustainable growth. Stakeholders across the pharmaceutical, healthcare, and public health sectors must collaborate to address disparities in access and ensure robust coverage across all populations.
Conclusion
The U.S. pneumococcal vaccine market represents a vital segment of the country’s immunization landscape, offering significant public health and commercial opportunities. With strong leadership from major vaccine manufacturers and unwavering government support for vaccine immunization programs, the market is expected to remain on a solid growth trajectory.
As innovation continues and awareness increases, the role of conjugate vaccines in both pediatric and adult vaccination schedules will expand, reinforcing the nation’s defense against pneumococcal disease.
More Trending Latest Reports By Polaris Market Research:
Cholesterol Testing Products and Services Market
Clinical Operations and Development Market
Liver Health Supplements Market
Medical Specimen Tracking System Market
Neuroplasticity Enhancement Devices Market
Remote Surgery Technology Platforms Market
Hemostasis and Tissue Sealing Agents Market
Comments
Post a Comment